Nedosiran
Based on 1 publication(s) in Google Scholar
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate.
For research use only. We do not sell to patients.
- Purity: 92.35%
- CAS No.: 2266591-83-5
- Formula: C662H865F19N231O413P57S6
- Molecular Weight:20985.12
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Nedosiran
More
Biological Activity
Nedosiran is a synthetic, double-stranded RNA oligonucleotide (i.e., small interfering RNA [siRNA]) designed to target the mRNA encoding LDHA[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Nedosiran specially inhibits hepatic expression of lactate dehydrogenase (LDHA)[3].
Nedosiran is a double-strand siRNA molecule that is conjugated with GalNAc, which takes advantage of the aforementioned unique asialoglycoprotein receptor (ASGPR) delivery system in the liver. Nedosiran is administered by monthly subcutaneous injection. Nedosiran decreases plasma oxalate in animal models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2266591-83-5
-
Appearance Solid
-
Molecular Weight 20985.12
-
Formula C662H865F19N231O413P57S6
-
Color White to off-white
-
SMILES
[Nedosiran]
-
Synonyms
DCR-PHXC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Drug Metab Dispos
Comparative evaluation of ultrafiltration and EMSA formats for siRNA plasma protein binding: Methodological determinants and artifacts. [Abstract]2026 Jun;54(6):100301. PMID: 42214258
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149. [Content Brief]
[2]. Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098. [Content Brief]
[3]. Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2021 May 22. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nedosiran Related Classifications
HY-132606 Related Classifications
Powered by Bioz